دورية أكاديمية
أعرض في EDS

Capecitabine-Related Thrombotic Microangiopathy.

التفاصيل البيبلوغرافية
العنوان: Capecitabine-Related Thrombotic Microangiopathy.
المؤلفون: Mateo FJP; Medical Oncology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain. fpelegrin@santpau.cat., Guasch AD; Nephrology Department, Fundació Puigvert, Barcelona, Spain., Pineda JAG; Department of Pathology, Fundació Puigvert, Barcelona, Spain., Manrique ACV; Medical Oncology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain., Cullell BM; Medical Oncology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain., López-Bravo DP; Medical Oncology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain., Díaz JG; Medical Oncology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain., Cascón AP; Medical Oncology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain., Freiria XB; Nephrology Department, Fundació Puigvert, Barcelona, Spain.
المصدر: Journal of gastrointestinal cancer [J Gastrointest Cancer] 2024 Jun; Vol. 55 (2), pp. 965-968. Date of Electronic Publication: 2024 Jan 04.
نوع المنشور: Case Reports; Journal Article
اللغة: English
بيانات الدورية: Publisher: Springer Science+Business Media Country of Publication: United States NLM ID: 101479627 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1941-6636 (Electronic) NLM ISO Abbreviation: J Gastrointest Cancer Subsets: MEDLINE
أسماء مطبوعة: Publication: 2010- : New York : Springer Science+Business Media
Original Publication: New York, NY : Humana Press
مواضيع طبية MeSH: Capecitabine*/adverse effects , Thrombotic Microangiopathies*/chemically induced , Thrombotic Microangiopathies*/pathology , Thrombotic Microangiopathies*/diagnosis , Antimetabolites, Antineoplastic*/adverse effects, Humans ; Female ; Aged, 80 and over ; Adenocarcinoma/drug therapy ; Adenocarcinoma/pathology ; Colonic Neoplasms/drug therapy ; Colonic Neoplasms/pathology
مستخلص: Purpose: Renal injury is common in cancer patients and its etiology is multifactorial. Different patterns of renal histological lesions have been described in relation to oncologic treatments, notably acute tubular necrosis and tubulointerstitial nephritis, but also thrombotic microangiopathy (TMA).
Methods: We report a case of TMA secondary to capecitabine in an 82-year-old woman diagnosed with localized colon adenocarcinoma.
Results: The patient, with previous normal kidney function, presented with renal impairment during the fourth cycle of chemotherapy. After potential nephrotoxic factors were ruled out, capecitabine was discontinued and a kidney biopsy was performed, which displayed TMA lesions. An improvement in renal function was observed after definitive cessation of cytotoxic chemotherapy. Although rare, renal toxicity in the form of TMA may be associated with the use of cytotoxic agents such as gemcitabine, but there is no reported evidence of its association to capecitabine. Early withdrawal of the drug and nephrology consultation is necessary to prevent irreversible damage.
Conclusion: We describe, to our knowledge, the first case reported in the literature regarding the possible association of TMA and capecitabine.
(© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.)
References: Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49. (PMID: 10.3322/caac.21660)
Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17–48. (PMID: 10.3322/caac.21763)
BJ R. Capecitabine. In: Enna SJ, Bylund DB, editors. xPharm: the comprehensive pharmacology reference. New York: Elsevier; 2007. p. 1–4.
Launay-Vacher V, Oudard S, Janus N, Gligorov J, Pourrat X, Rixe O, et al. Prevalence of renal insufficiency in cancer patients and implications for anticancer drug management: the renal insufficiency and anticancer medications (IRMA) study. Cancer. 2007;110(6):1376–84. (PMID: 10.1002/cncr.22904)
Gupta S, Portales-Castillo I, Daher A, Kitchlu A. Conventional chemotherapy nephrotoxicity. Adv Chronic Kidney Dis. 2021;28(5):402–14.e1. Available from: https://doi.org/10.1053/j.ackd.2021.08.001 .
Fı L, Irigoyen A, Valladares-ayerbes M, Castellanos J. Phase II study of irinotecan as first-line. 2001;704–11.
Rödel C, Liersch T, Hermann RM, Arnold D, Reese T, Hipp M, et al. Multicenter phase II trial of chemoradiation with oxaliplatin for rectal cancer. J Clin Oncol. 2007;25(1):110–7. (PMID: 10.1200/JCO.2006.08.3675)
Willeke F, Horisberger K, Kraus-Tiefenbacher U, Wenz F, Leitner A, Hochhaus A, et al. A phase II study of capecitabine and irinotecan in combination with concurrent pelvic radiotherapy (CapIri-RT) as neoadjuvant treatment of locally advanced rectal cancer. Br J Cancer. 2007;96(6):912–7. (PMID: 10.1038/sj.bjc.6603645)
Wilke H, Glynne-Jones R, Thaler J, Adenis A, Preusser P, Aguilar EA, et al. Cetuximab plus irinotecan in heavily pretreated metastatic colorectal cancer progressing on irinotecan: MABEL study. J Clin Oncol. 2008;26(33):5335–43. (PMID: 10.1200/JCO.2008.16.3758)
Lim AR, Kim JH, Hyun MH, Kim YH, Lee S. Prognostic factors for renal function deterioration during palliative first-line chemotherapy for metastatic colorectal cancer: a retrospective study. Support Care Cancer. 2022;30(10):8129–37. Available from: https://doi.org/10.1007/s00520-022-07249-2 .
Troxell ML, Higgins JP, Kambham N. Antineoplastic treatment and renal injury: an update on renal pathology due to cytotoxic and targeted therapies. Adv Anat Pathol. 2016;23(5):310–29. (PMID: 10.1097/PAP.0000000000000122)
Izzedine H, Perazella MA. Thrombotic microangiopathy, cancer, and cancer drugs. Am J Kidney Dis. 2015;66(5):857–68. Available from: https://doi.org/10.1053/j.ajkd.2015.02.340 .
Kintzel PE. Anticancer drug-induced kidney disorders: incidence, prevention and management. Drug Saf. 2001;24(1):19–38. (PMID: 10.2165/00002018-200124010-00003)
Sonnenblick A, Meirovitz A. Renal tubular acidosis secondary to capecitabine, oxaliplatin, and cetuximab treatment in a patient with metastatic colon carcinoma: a case report and review of the literature. Int J Clin Oncol. 2010;15(4):420–2. (PMID: 10.1007/s10147-010-0050-0)
Ferrari S, Zolezzi C, Cesari M, Fasano MC, Lamanna G BG. Prospective evaluation of high-dose ifosfamide-related nephrotoxicity in young adults patients with recurrent osteosarcoma previously treated with cisplatin, methotrexate and standard-dose ifosfamide.pdf. Anticancer Drugs. 1999;10:25–31.
Cassidy J, Twelves C, Van Cutsem E, Hoff P, Bajetta E, Boyer M, et al. First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann Oncol. 2002;13(4):566–75. Available from: https://doi.org/10.1093/annonc/mdf089 .
Al-Nouri ZL, Reese JA, Terrell DR, Vesely SK, George JN. Drug-induced thrombotic microangiopathy: a systematic review of published reports. Blood. 2015;125(4):616–8. (PMID: 10.1182/blood-2014-11-611335)
Daviet F, Rouby F, Poullin P, Moussi-Francès J, Sallée M, Burtey S, et al. Thrombotic microangiopathy associated with gemcitabine use: presentation and outcome in a national French retrospective cohort. Br J Clin Pharmacol. 2019;85(2):403–12. (PMID: 10.1111/bcp.13808)
Burns ST, Damon L, Akagi N, Laszik Z, Ko AH. Rapid improvement in gemcitabine-associated thrombotic microangiopathy after a single dose of eculizumab: case report and review of the literature. Anticancer Res. 2020;40(7):3995–4000. (PMID: 10.21873/anticanres.14393)
فهرسة مساهمة: Keywords: Capecitabine; Colorectal cancer; Nephrotoxicity; Thrombotic microangiopathy
المشرفين على المادة: 6804DJ8Z9U (Capecitabine)
0 (Antimetabolites, Antineoplastic)
تواريخ الأحداث: Date Created: 20240104 Date Completed: 20240619 Latest Revision: 20240620
رمز التحديث: 20240621
DOI: 10.1007/s12029-023-00993-6
PMID: 38175385
قاعدة البيانات: MEDLINE
الوصف
تدمد:1941-6636
DOI:10.1007/s12029-023-00993-6